22. January 2008 03:27
Ranbaxy Laboratories Limited (Ranbaxy) has announced that it has settled all matters relating to possible patent litigation with GlaxoSmithKline relating to Sumatriptan Succinate Tablets, the generic version of GlaxoSmithKline's Imitrex Tablets.
The terms of the settlement provide that Ranbaxy may distribute a generic version of Sumatriptan Succinate Tablets (in the 25 mg, 50 mg and 100 mg strengths) in the United States with an expected launch date in December, 2008.
Additional terms of the settlement agreement were not disclosed.
The annual market sales for Sumatriptan Succinate (Imitrex(R)) were USD 985 million (IMS-MAT: Sept 2007).
http://www.ranbaxy.com/
News-Medical.Net provides this medical information service in accordance
with these
terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.
Subscribe